Fewer appointments for those who require both vaccines
As Britain prepared for a winter of overlapping respiratory threats, a University of Bristol study offered public health planners a quiet but consequential reassurance: receiving a COVID-19 vaccine and a flu shot in the same appointment is safe, effective, and broadly acceptable to patients. Conducted across twelve sites in England and Wales with 679 volunteers, the research found that simultaneous administration in opposite arms produced only mild to moderate side effects, with neither vaccine diminishing the immune response of the other. In a season when both viruses threatened to surge together, the study suggested that simplicity and safety need not be in conflict.
- Britain faced a dangerous convergence — loosening COVID restrictions and the return of indoor gatherings threatened to unleash both flu and coronavirus simultaneously this winter.
- Public health planners were caught between two urgent campaigns: the largest flu vaccination drive in British history and a rolling COVID-19 booster rollout for millions of vulnerable people.
- The central fear — that combining both vaccines at once might overwhelm the immune system or produce serious side effects — was directly tested and effectively dispelled by the Bristol research.
- An overwhelming 97% of participants said they would willingly receive both vaccines in a single appointment, signaling that the public was ready to embrace a more streamlined approach.
- The findings were fast-tracked to the Joint Committee on Vaccination and Immunisation, bypassing the usual publication timeline so that policymakers could begin reshaping winter vaccination strategy immediately.
As Britain braced for a difficult winter — one where COVID-19 restrictions were fading and flu cases threatened to surge — public health planners faced a pressing logistical question: could both vaccines be given at the same appointment without risk?
Researchers at the University of Bristol answered that question on Thursday. A study involving 679 volunteers across twelve sites in England and Wales found that receiving a COVID-19 shot and a flu vaccine simultaneously, administered in opposite arms, produced only mild to moderate side effects. Crucially, neither vaccine weakened the immune response generated by the other. The study tested three different flu vaccines paired with either the Pfizer or AstraZeneca COVID-19 shot across varying schedules.
The implications for an overstretched healthcare system were immediate. Ninety-seven percent of participants said they would be willing to receive both vaccines in a single future appointment — a finding that pointed toward fewer clinic visits, reduced scheduling pressure, and potentially higher vaccination rates overall. Chief investigator Rajeka Lazarus called it "a really positive step" for patients who require both vaccines.
The results were presented directly to Britain's Joint Committee on Vaccination and Immunisation, released as a pre-print so that policymakers could begin planning without waiting for full journal publication. With two viruses poised to circulate heavily at once, the study offered something rare in a complex public health moment: a straightforward answer that made the path forward a little simpler.
As Britain braced for what officials feared would be a punishing winter—one where COVID-19 restrictions were loosening, social distancing was fading, and flu cases threatened to surge—a practical question had begun to occupy public health planners: Could people receive both a coronavirus vaccine and a flu shot at the same appointment, or would doing so overwhelm the immune system and produce dangerous side effects?
A study led by researchers at the University of Bristol provided an answer on Thursday: yes, it was safe. Not only safe, but the side effects reported were typically mild to moderate, and neither vaccine compromised the immune response generated by the other. The finding arrived at a moment when the British government was preparing what it called the largest flu vaccination campaign in its history, while simultaneously rolling out COVID-19 boosters to elderly people, vulnerable populations, and healthcare workers.
The research involved 679 volunteers across twelve sites in England and Wales. Participants were divided into groups that received different combinations of vaccines on different schedules. Some received a COVID-19 shot and a flu vaccine on the same day, administered in opposite arms, followed by a placebo at a second visit. Others received a COVID-19 shot and a placebo on day one, then the flu vaccine on day two. The researchers tested three different flu vaccines paired with either the Pfizer or AstraZeneca COVID-19 shot.
The results were straightforward enough to reshape how vaccination clinics might operate. Ninety-seven percent of study participants said they would be willing to receive both vaccines at a single appointment in the future. For a healthcare system preparing for winter surge, this was significant: fewer appointments meant fewer visits to clinics, less strain on scheduling, and potentially higher vaccination rates overall. Rajeka Lazarus, the study's chief investigator, framed it as a practical win. "This is a really positive step which could mean fewer appointments for those who require both vaccines," she said.
The findings were presented to Britain's Joint Committee on Vaccination and Immunisation, the body responsible for advising the government on vaccine policy. The committee would now consider whether to recommend simultaneous vaccination as standard practice. The full results were expected to be published in the Lancet, though the study had been released as a pre-print to allow policymakers to begin planning immediately.
What made this study matter was timing and context. Winter in the Northern Hemisphere typically brings a surge in respiratory illness. With COVID-19 restrictions being dismantled and people returning to closer contact indoors, health officials worried that both viruses would circulate heavily at once. A single appointment that addressed both threats—without compromising either vaccine's effectiveness or burdening patients with side effects—could simplify a complex public health challenge. The study suggested that such an approach was not only feasible but acceptable to the people who would receive it.
Citações Notáveis
This is a really positive step which could mean fewer appointments for those who require both vaccines.— Rajeka Lazarus, chief investigator
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter whether these two vaccines can be given on the same day? Couldn't people just come back a week later for the second one?
They could, but that assumes people will actually come back. In practice, missed second appointments are common. If you can vaccinate someone against both threats in one visit, you're more likely to reach them before winter hits. It's efficiency, but it's also equity—fewer trips means fewer barriers for people who struggle to get time off work or arrange transport.
The study found side effects were mild to moderate. What does that actually mean? Were people uncomfortable?
Mild to moderate typically means soreness at the injection site, maybe some fatigue or a low fever for a day or two. Nothing that required hospitalization or serious intervention. The key finding was that adding a second vaccine didn't make side effects worse than you'd expect from either vaccine alone.
Ninety-seven percent said they'd do it again. That's a high number. Were people surprised it went smoothly?
Likely. There's often anxiety around vaccines, especially new ones. When people experience something they feared—two shots, same day—and it turns out fine, they're more willing to trust the process next time. That willingness matters when you're trying to vaccinate millions of people.
This was presented to the Joint Committee on Vaccination and Immunisation. What happens now?
They'll weigh the evidence and decide whether to recommend simultaneous vaccination as official policy. If they do, clinics will change how they schedule and staff appointments. It becomes the standard, not the exception. That's when the real-world impact happens.